Sarcoma  >>  Herceptin (trastuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Herceptin (trastuzumab) / Roche
NCT00005033: Trastuzumab in Treating Patients With Recurrent Osteosarcoma

Completed
2
US
trastuzumab, conventional surgery
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Sarcoma
 
08/04
NCT00023998: Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Completed
2
80
US
doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, cisplatin, CACP, CDDP, CPDD, DDP, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, leucovorin calcium, CF, CFR, LV, filgrastim, G-CSF, Neupogen, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation, etoposide, EPEG, VP-16, VP-16-213, ifosfamide, Cyfos, Holoxan, IFF, IFX, IPP, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, laboratory biomarker analysis
National Cancer Institute (NCI)
Metastatic Osteosarcoma
11/05
05/07
NCT00104949: Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Completed
2
40
US
trastuzumab
Southwest Oncology Group, National Cancer Institute (NCI)
Sarcoma
 
08/07
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT04464967: Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Withdrawn
1/2
0
NA
SNK01, Trastuzumab, Herceptin, Cetuximab, Erbitux
NKGen Biotech, Inc.
Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, Esophageal Cancer, Ovarian Cancer, Endometrium Cancer, Bladder Cancer, Pancreatic Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cervical Cancer, Sarcoma
08/22
02/23

Download Options